Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes

Piero Ruggenenti; Bettina J. Kraus; Silvio E. Inzucchi; Bernard Zinman; Stefan Hantel; Michaela Mattheus; Maximilian von Eynatten; Giuseppe Remuzzi; Audrey Koitka‐Weber; Christoph Wanner

doi:10.1016/j.eclinm.2021.101240

Related publications

Letter2019

Reducing Risk of Adverse Cardiovascular and Renal Outcomes for Patients with Atrial Fibrillation and Type 2 Diabetes

Stephanie L. Harrison, Deirdre A. Lane, Professor Gregory Lip

Article2012

Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes

Piero Ruggenenti, Esteban Porrini, Flavio Gaspari, Nicola Motterlini, Antonio Cannatà, Fabiola Carrara, Claudia Cella, Silvia Ferrari, Nadia Stucchi, Aneliya Parvanova, Ilian Iliev, Alessandro Roberto Dodesini, Roberto Trevisan, Antonio Bossi, Jelka Zaletel, Giuseppe Remuzzi

Article2013

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ‐Schmidt, Angie Goldsberry, Mark T. Houser, Melissa Krauth, Hiddo J.L. Heerspink, John J.V. McMurray, Colin J. Meyer, Hans‐Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow

Article2017

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study

Sergio Iannazzo, Edoardo Mannucci, Odette S. Reifsnider, Aldo Maggioni

Article2024

Abstract MP31: Incident Type 2 Diabetes Onset Age and Duration, Mortality Risk, and Loss in Life Expectancy

Yin Zhang, Mingyang Song, Molin Wang, Ellen Hertzmark, Kana Wu, A. Heather Eliassen, Lorelei A. Mucci, Qi Sun, Meir J. Stampfer, Walter C. Willett, Frank B Hu, Edward L. Giovannucci